MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Last trade$3.17
Day change-$0.01 (-0.31%)
Day range$3.08 – $3.24
Volume1,328,516
Market cap$464M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$464.04M
Price / earnings
—
Price / book
2.2×
Price / sales
1.53×
EV / sales
1.13×
EV / EBITDA
-19.83×
Profitability
Earnings per share
-$0.13
Return on assets
-7.25%
Return on equity
-9.09%
Dividend yield
0.35%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.35×
Quick ratio
3.84×
Cash ratio
2.81×
Cash flow
Price / cash flow
22.38×
Price / free cash flow
24.27×
Free cash flow
$19.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MDXG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$62.28M
$64.36M
$58.99M
$118.1M
$113.73M
$98.61M
$88.21M
$92.91M
Cost of revenue
$12.58M
$19.98M
$17.37M
$19.06M
$18.72M
$18.68M
$16.56M
$16.91M
Gross profit
$49.7M
$44.38M
$41.62M
$99.04M
$95.01M
$79.92M
$71.65M
$76M
Selling, general and administrative
$58.31M
$59.78M
$53.23M
$73.07M
$69M
$64.15M
$59.97M
$61.04M
Research and development
$2.8M
$2.78M
$4.14M
$4.76M
$3.7M
$3.3M
$3.33M
$3.57M
Total operating expenses
$61.4M
$62.85M
$57.67M
$77.96M
$72.82M
$67.55M
$63.4M
$64.5M
Operating income
-$11.7M
-$18.47M
-$16.05M
$21.08M
$22.19M
$12.37M
$8.25M
$11.5M
Interest expense
$776K
$788K
$886K
$0
$785K
$738K
$506K
$0
Income before taxes
-$11.06M
-$17.78M
-$15.33M
$21.8M
$22.85M
$13.01M
$8.61M
$11.25M
Income taxes
-$2.38M
-$2.94M
-$4.47M
$6.6M
$6.1M
$3.39M
$1.59M
$3.81M
Net income
-$8.68M
-$14.84M
-$10.86M
$15.19M
$16.75M
$9.62M
$7.02M
$7.44M
Net income attributable to common shareholders
-$8.68M
-$14.84M
-$10.86M
$15.19M
$16.75M
$9.62M
$7.02M
$7.44M
EBITDA
-$10.24M
-$16.94M
-$14.43M
$24.3M
$27.48M
$15.54M
$11.45M
$14.14M
Basic earnings per share
-$0.06
-$0.10
-$0.07
$0.10
$0.11
$0.07
$0.05
$0.05
Diluted earnings per share
-$0.06
-$0.10
$0.00
$0.10
$0.11
$0.06
$0.00
$0.05
Recent news
Company coverage with links to the original publishers.
MiMedx Group, Inc. announced it will report Q3 2026 financial results on October 28, 2026, followed by a webcast and conference call at 4:30 p.m. ET. The company also announced a favorable federal court ruling vacating FDA determinations regarding AXIOFILL's regulatory classification as a biological product.
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.
MiMedx Group, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a webcast and conference call with senior management at 4:30 p.m. Eastern Time to review the results.
MIMEDX marks the 15th anniversary of its flagship placental allograft products EPIFIX and AMNIOFIX, which have been featured in nearly 100 clinical and scientific publications including seven randomized controlled trials. The company positions these products as the industry's most studied placental allografts, used across multiple surgical specialties for wound care and surgical recovery applications.
MiMedx Group will report its third quarter 2025 financial results on October 29, 2025, with a webcast and conference call scheduled for 4:30 p.m. Eastern Time.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.